23,884 Shares in Pfizer Inc. $PFE Purchased by Compass Financial Management LLC

Compass Financial Management LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 23,884 shares of the biopharmaceutical company’s stock, valued at approximately $578,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Evolution Wealth Management Inc. lifted its stake in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer in the 4th quarter valued at about $26,000. Keb Asset Management LLC acquired a new position in shares of Pfizer during the 2nd quarter worth about $26,000. HFM Investment Advisors LLC raised its holdings in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the period. Finally, Global Trust Asset Management LLC raised its holdings in shares of Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 650 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE:PFE opened at $27.97 on Tuesday. The stock has a 50 day simple moving average of $25.34 and a 200 day simple moving average of $26.26. The stock has a market cap of $159.41 billion, a P/E ratio of 36.80 and a beta of 0.34. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the firm posted $0.78 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.1%. Pfizer’s payout ratio is 226.32%.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reduced their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Guggenheim reduced their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. Weiss Ratings downgraded Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 17th. Finally, Bank of America reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.28.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.